JPWO2022020107A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022020107A5 JPWO2022020107A5 JP2023504634A JP2023504634A JPWO2022020107A5 JP WO2022020107 A5 JPWO2022020107 A5 JP WO2022020107A5 JP 2023504634 A JP2023504634 A JP 2023504634A JP 2023504634 A JP2023504634 A JP 2023504634A JP WO2022020107 A5 JPWO2022020107 A5 JP WO2022020107A5
- Authority
- JP
- Japan
- Prior art keywords
- exon
- conjugate
- antibody
- complex
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055777P | 2020-07-23 | 2020-07-23 | |
| US63/055,777 | 2020-07-23 | ||
| US202063069077P | 2020-08-23 | 2020-08-23 | |
| US63/069,077 | 2020-08-23 | ||
| US202163143829P | 2021-01-30 | 2021-01-30 | |
| US63/143,829 | 2021-01-30 | ||
| PCT/US2021/040998 WO2022020107A1 (en) | 2020-07-23 | 2021-07-09 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535073A JP2023535073A (ja) | 2023-08-15 |
| JPWO2022020107A5 true JPWO2022020107A5 (enExample) | 2024-07-18 |
Family
ID=79728346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504634A Pending JP2023535073A (ja) | 2020-07-23 | 2021-07-09 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230285586A1 (enExample) |
| EP (1) | EP4185330A4 (enExample) |
| JP (1) | JP2023535073A (enExample) |
| KR (1) | KR20230044242A (enExample) |
| CN (1) | CN116368150A (enExample) |
| AU (1) | AU2021312709A1 (enExample) |
| BR (1) | BR112023001125A2 (enExample) |
| CA (1) | CA3186752A1 (enExample) |
| IL (1) | IL299662A (enExample) |
| MX (1) | MX2023000984A (enExample) |
| WO (1) | WO2022020107A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| AU2020263487A1 (en) | 2019-04-25 | 2021-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| KR20230117182A (ko) * | 2020-12-04 | 2023-08-07 | 다인 세라퓨틱스, 인크. | 항체-올리고뉴클레오티드 복합체 및 그의 용도 |
| MX2023014417A (es) | 2021-06-23 | 2023-12-15 | Nippon Shinyaku Co Ltd | Combinacion de oligomeros antisentido. |
| EP4366783A4 (en) * | 2021-07-09 | 2025-08-27 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| AU2022307934A1 (en) * | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US20240382609A1 (en) * | 2021-07-09 | 2024-11-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| WO2024226471A2 (en) | 2023-04-24 | 2024-10-31 | Biomarin Pharmaceutical Inc. | Compositions and methods for treating stxbp1 disorders |
| WO2025024334A1 (en) | 2023-07-21 | 2025-01-30 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
| SI3097122T1 (sl) * | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo |
| KR20250073514A (ko) * | 2015-06-24 | 2025-05-27 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체 |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| CN111770757A (zh) * | 2017-09-22 | 2020-10-13 | 艾维迪提生物科学公司 | 诱导外显子跳读的核酸-多肽组合物和方法 |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| EP3829594A4 (en) * | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
| SG11202100934PA (en) * | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN113543807A (zh) * | 2019-01-04 | 2021-10-22 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| US20230111212A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| KR20230041760A (ko) * | 2020-07-23 | 2023-03-24 | 다인 세라퓨틱스, 인크. | 항-트랜스페린 수용체 (tfr) 항체 및 그의 용도 |
-
2021
- 2021-07-09 KR KR1020237005853A patent/KR20230044242A/ko active Pending
- 2021-07-09 IL IL299662A patent/IL299662A/en unknown
- 2021-07-09 BR BR112023001125A patent/BR112023001125A2/pt unknown
- 2021-07-09 AU AU2021312709A patent/AU2021312709A1/en active Pending
- 2021-07-09 EP EP21846687.8A patent/EP4185330A4/en active Pending
- 2021-07-09 WO PCT/US2021/040998 patent/WO2022020107A1/en not_active Ceased
- 2021-07-09 CN CN202180064570.5A patent/CN116368150A/zh active Pending
- 2021-07-09 JP JP2023504634A patent/JP2023535073A/ja active Pending
- 2021-07-09 MX MX2023000984A patent/MX2023000984A/es unknown
- 2021-07-09 CA CA3186752A patent/CA3186752A1/en active Pending
- 2021-07-09 US US18/017,179 patent/US20230285586A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022020107A5 (enExample) | ||
| JP2024160045A5 (enExample) | ||
| JPWO2020028832A5 (enExample) | ||
| JP2025067909A5 (enExample) | ||
| JP2023015095A5 (enExample) | ||
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and their uses for the treatment of dystrophinopathy | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JPWO2021142307A5 (enExample) | ||
| IL309912A (en) | Muscle targeting complexes and their uses for the treatment of dystrophinopathy | |
| JPWO2021142227A5 (enExample) | ||
| JPWO2020028857A5 (enExample) | ||
| KR20230042713A (ko) | 근육 표적화 복합체 및 근긴장성 이영양증을 치료하기 위한 그의 용도 | |
| JPWO2020028864A5 (enExample) | ||
| IL304048A (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JPWO2023283615A5 (enExample) | ||
| JP2023527638A (ja) | 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法 | |
| JPWO2022026152A5 (enExample) | ||
| CN120282986A (zh) | 肌肉靶向复合物及其用于跳读dmd基因的外显子45的用途 | |
| KR20250004771A (ko) | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여 | |
| JPWO2018129384A5 (enExample) | ||
| JPWO2021142313A5 (enExample) | ||
| JPWO2020028861A5 (enExample) | ||
| JPWO2020028841A5 (enExample) |